InsidersTradesSigma
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (12 ops.)
Insider track record
OtherDisclosed buys
9
Disclosed sells
12
T+90 hit rate
46%
T+90 mean return
-1.1%
Across 28 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by BIENAIME JEAN JACQUES. Insider active across 4 companies, notably Biomarin Pharmaceutical INC. In total, 71 filings have been logged. Split: 9 buys · 12 sells. Total volume traded: €2.2m. History available since 30 April 2021. The latest transaction was filed on 29 May 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations71 total
200 shares@ US$223.7621.7% of flowOrdinary SharesSEC:0001610717-26-000177:0
Ideal exit: 23 Feb 2027 (T+270)
200 shares@ US$222.3021.5% of flowOrdinary SharesSEC:0001610717-26-000177:1
Ideal exit: 23 Feb 2027 (T+270)
100 shares@ US$223.5010.8% of flowOrdinary SharesSEC:0001610717-26-000177:2
Ideal exit: 23 Feb 2027 (T+270)
15,000 shares@ US$84.530.0057% mcap50.0% of flowCommon StockSEC:0001221590-26-000011:0
13,059 shares@ US$97.100.0057% mcap50.0% of flowCommon StockSEC:0001221590-26-000011:1
200 shares@ US$236.23522.8% of flowOrdinary SharesSEC:0001610717-26-000161:0
Ideal exit: 20 Feb 2027 (T+270)
200 shares@ US$239.367523.1% of flowOrdinary SharesSEC:0001610717-26-000161:1
Ideal exit: 20 Feb 2027 (T+270)
7,800 shares@ US$7.7825.2% of flowCommon StockSEC:0001415889-25-009019:0
Ideal exit: 20 Dec 2025 (T+270)
7,000 shares@ US$8.2123.8% of flowCommon StockSEC:0001415889-25-008920:0
Ideal exit: 19 Dec 2025 (T+270)
7,000 shares@ US$13.94439.9% of flowCommon StockSEC:0001415889-24-021659:0
Ideal exit: 13 May 2025 (T+270)
2,830 shares0Common StockSEC:0000879169-24-000097:0
2,000 shares@ US$13.569911.2% of flowCommon StockSEC:0001415889-24-014107:0
Ideal exit: 15 Feb 2025 (T+270)
1,202 shares@ US$77.050.4% of flowCommon StockSEC:0001048477-24-000086:0
20,000 shares@ US$63.105.5% of flowCommon StockSEC:0001048477-24-000079:0
20,000 shares@ US$63.105.5% of flowCommon StockSEC:0001048477-24-000063:0
85,209 shares@ US$83.8730.6% of flowCommon StockSEC:0001048477-24-000038:0
1,000 shares@ US$85.510.4% of flowCommon StockSEC:0001048477-24-000032:0
82,700 shares0Common StockSEC:0001048477-24-000018:0
40 shares@ US$92.59750.0% of flowCommon StockSEC:0001048477-24-000010:0
50 shares@ US$99.05180.0% of flowCommon StockSEC:0001048477-24-000002:0
10,000 shares@ US$63.102.7% of flowCommon StockSEC:0001048477-23-000064:0
10 shares@ US$85.56640.0% of flowCommon StockSEC:0001048477-23-000057:0
4,000 shares@ US$88.101.5% of flowCommon StockSEC:0001048477-23-000031:0
2,505 shares0Common StockSEC:0001209191-23-037794:0
39,130 shares@ US$67.8111.3% of flowCommon StockSEC:0001209191-23-029870:0
25 of 71 declarations
About BIENAIME JEAN JACQUES
Jean Jacques Bienaime is an executive at BioMarin Pharmaceutical Inc.
